share_log

NewAmsterdam Pharma Debuts As Publicly Traded Co. Focused On Developing Obicetrapib As A Potential Preferred Therapy For High Risk Cardiovascular Disease Patients

NewAmsterdam Pharma Debuts As Publicly Traded Co. Focused On Developing Obicetrapib As A Potential Preferred Therapy For High Risk Cardiovascular Disease Patients

新阿姆斯特丹製藥公司首次亮相為上市交易公司.專注於開發奧巴塞曲比作為高風險心血管疾病患者的潛在首選療法
Benzinga Real-time News ·  2022/11/23 08:04

-- Business combination transaction with Frazier Lifesciences Acquisition Corporation, a special purpose acquisition company sponsored by an affiliate of Frazier Healthcare Partners, completed on November 22, 2022 --

-- 與 Frazier Lifesciences 收購公司（由 Frazier 醫療保健合作夥伴的附屬公司贊助的特殊目的收購公司）的業務合併交易已於 11 月完成 第二十二章--

-- Closed concurrent, oversubscribed and upsized approximately $235 million private investment in public equity ("PIPE"), led by Frazier Healthcare Partners and Bain Capital Life Sciences --

--由 Frazier 醫療保健合作夥伴和貝恩資本生命科學領導的封閉式並發，超額認購和增加了大約 2.35 億美元的公共股權私人投資（「PIPE」）-

-- Gross proceeds from the transactions totaled approximately $328 million, combining approximately $93 million from the former FLAC trust account (reflecting a final redemption rate of approximately 32 percent) and the concurrent PIPE financing; expected to extend cash runway through 2026, beyond all expected Phase 3 readouts for cardiovascular disease, including PREVAIL CVOT study --

--來自交易的總收益總額約 3.27 億美元, 結合前 FLAC 信託帳戶的約 9300 萬美元（反映了約 32％ 的最終贖回率）和並發的 PIPE 融資；預計將延長現金跑道到 2026 年，超出了心血管疾病的所有預期第三階段讀數，包括 PRIVAIL CVOT 研究---

-- Listed company to be named NewAmsterdam Pharma Company N.V. --

--上市公司將被命名為新阿姆斯特丹製藥公司 N.V.-

-- Ordinary shares and warrants to commence trading on the Nasdaq Capital Market under the ticker symbols "NAMS" and "NAMSW," respectively on November 23 –

--普通股和認股權證將於 11 月 23 日分別以「NAMS」和「NAMSW」在納斯達克資本市場開始交易 —

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論